levodopa has been researched along with entacapone in 260 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 39 (15.00) | 18.2507 |
| 2000's | 117 (45.00) | 29.6817 |
| 2010's | 81 (31.15) | 24.3611 |
| 2020's | 23 (8.85) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Armirotti, A; Barone, M; Bertozzi, SM; Biagi, E; Brigidi, P; Candela, M; Cavalli, A; Falchi, F; Rampelli, S; Turroni, S | 1 |
| Männistö, PT; Tuomainen, P; Tuominen, RK | 1 |
| Männistö, PT; Törnwall, M | 2 |
| Cedarbaum, JM; Guttman, M; Leger, G | 1 |
| Kaakkola, S; Kask, A; Männistö, PT; Törnwall, M; Tuomainen, P | 1 |
| Lang, A; Männistö, PT; Rauhala, P; Vasar, E | 1 |
| Deleu, D; Ebinger, G; Michotte, Y; Sarre, S | 1 |
| Gordin, A; Kaakkola, S; Männistö, PT | 1 |
| Brooks, DJ; Burn, DJ; Lammertsma, AA; Luthra, S; Morrish, PK; Osman, S; Sawle, GV; Snow, BJ | 1 |
| Illi, A; Keränen, T; Myllylä, VV; Sotaniemi, KA; Suominen, K | 1 |
| Bovingdon, M; Gordin, A; Lees, AJ; Merello, M; Webster, R | 1 |
| Beckner, RM; Berggren, K; Carter, JH; Gancher, ST; Gordin, A; Hammerstad, JP; Nutt, JG; Stone, CK; Woodward, WR | 1 |
| Ahtila, S; Gordin, A; Kaakkola, S; Rita, H; Teräväinen, H | 1 |
| Cedarbaum, JM; Evans, A; Gjedde, A; Guttman, M; Kuwabara, H; Léger, G; Reches, A | 1 |
| Gordin, A; Harjola, VP; Karlsson, M; Keränen, T; Korpela, K; Pentikäinen, PJ; Rita, H; Seppälä, L; Wikberg, T | 1 |
| Rinne, UK; Ruottinen, HM | 4 |
| Ahtila, S; Gordin, A; Heinävaara, S; Kaakkola, S; Karlsson, M; Korpela, K; Männistö, PT; Tuomainen, P; Wikberg, T | 1 |
| Antila, S; Gordin, A; Keränen, T; Koulu, M; Scheinin, M; Sundberg, S; Wikberg, T | 1 |
| Bergström, M; Eriksson, B; Jacobsson, G; Långström, B; Lu, L; Marquez, M; Moulder, R; Ogren, M; Watanabe, Y | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Ahtila, S; Kaakkola, S; Lyytinen, J; Teräväinen, H; Tuomainen, P | 1 |
| Männistö, PT | 1 |
| Nutt, JG | 2 |
| Gordin, A; Jenner, P; Marsden, CD; Smith, LA | 1 |
| Adler, CH; Kurth, MC | 1 |
| Ahtee, L; Honkanen, A; Katajamäki, J; Lindén, IB; Piepponen, TP; Zharkovsky, A | 1 |
| Martínez-Martín, P; O'Brien, CF | 1 |
| Gordin, A; Karlsson, MO; Naukkarinen, TH; Rinne, UK; Ruottinen, HM; Trocóniz, IF | 1 |
| Larsen, JP; Rinne, UK; Siden, A; Worm-Petersen, J | 1 |
| Bornkessel, B | 1 |
| Phillips, P | 1 |
| Gordin, A; Huhtala, S; Huupponen, R; Korpela, K; Reinikainen, K; Rouru, J; Savontaus, E; Scheinin, M | 1 |
| Luer, MS | 1 |
| Ahlskog, JE | 2 |
| Jenner, P; MacKenzie, GM; Pearce, RK; Zeng, BY | 1 |
| Brooks, DJ; Gordin, A; Karlsson, M; Korpela, K; Pavese, N; Piccini, P | 1 |
| Waters, C | 1 |
| Brooks, DJ; Forsyth, D; Playfer, JR; Williams, AC | 1 |
| Dingemanse, J | 1 |
| Hubble, J; Kieburtz, K | 1 |
| Bergman, J; Eronen, E; Eskola, O; Niinivirta, M; Oikonen, V; Rinne, UK; Ruottinen, HM; Solin, O; Sonninen, P | 1 |
| Sternon, J; Supiot, F; Zegers de Beyl, D | 1 |
| Bourdeix, I; Delumeau, JC; Devaux, I; Durif, F; Pere, JJ | 1 |
| de Luis, P; del Real, MA; Gudín, M; Hernández, A; Ibáñez, R; Vaamonde, J | 1 |
| Masson, C | 1 |
| Gerlach, M; Kuhn, W; Lehnfeld, R; Riederer, P; Sontag, KH; Waldmeier, P; Xiao, AY | 1 |
| Gálvez-Jiménez, N; Hanson, MR | 1 |
| Bonanni, L; Di Iorio, A; Iacono, D; Onofrj, M; Thomas, A | 1 |
| Ball, J | 1 |
| Haapaniemi, H; Kultalahti, ER; Leinonen, M; Myllylä, VV | 1 |
| Halliwell, B; Jenner, P; Lyras, L; McKenzie, G; Pearce, RK; Zeng, BY | 1 |
| Gynther, J; Huuskonen, J; Järvinen, T; Leppänen, J; Nevalainen, T; Taipale, H | 1 |
| Sharif, AA | 1 |
| Deuschl, G; Gordin, A; Kultalahti, ER; Leinonen, M; Poewe, WH | 1 |
| Henchcliffe, C; Waters, C | 1 |
| Nuijten, MJ; Palmer, CS; Schmier, JK; Snyder, EH; Subedi, P | 1 |
| Heikkinen, H; Kaakkola, S; Kela, M; Laine, T; Puttonen, J; Reinikainen, K; Varhe, A | 1 |
| Haasio, K; Koponen, A; Nissinen, E; Penttilä, KE | 1 |
| Gordin, A; Kaakkola, S; Teräväinen, H | 2 |
| Gordin, A; Larsen, JP; Leinonen, M; Reinikainen, K; Sidén, A; Worm-Petersen, J | 1 |
| Bermejo, F; Bourdeix, I; Durif, F; Fénelon, G; Galiano, L; Giménez-Roldán, S; Montastruc, JL; Péré, JJ; Schadrack, J | 1 |
| Hansard, MJ; Jackson, MJ; Jenner, P; Maratos, E; Smith, LA | 1 |
| Brooks, DJ; Sagar, H | 1 |
| Blandini, F; Bono, G; Calandrella, D; Fancellu, R; Mangiagalli, A; Martignoni, E; Nappi, G; Pacchetti, C; Riboldazzi, G; Samuele, A | 1 |
| Benabou, R; Waters, C | 1 |
| Bernhard, G; Emre, M; Gershanik, O; Sauer, D | 1 |
| Ceballos-Baumann, A | 1 |
| Carboni, T; Curatola, L; Gobbato, R; Paci, C; Sanguigni, S | 1 |
| Battaglia, G; Grassini, P; Onofrj, M; Ruggieri, S; Stocchi, F; Vacca, L; Valente, M | 1 |
| Jenner, P | 1 |
| Olanow, CW; Stocchi, F | 1 |
| Hauser, RA | 2 |
| Stacy, M | 1 |
| Bremen, D; Kupsch, A; Trottenberg, T | 1 |
| Barbato, L; Bolner, A; Caraceni, T; Nordera, G; Stocchi, F | 1 |
| Gordin, A; Kaakkola, S; Kultalahti, ER; Lyytinen, J; Sovijärvi, A; Teräväinen, H | 1 |
| Takáts, A | 1 |
| Clarke, C; Gray, R; Ives, N; Wheatley, K | 1 |
| Bassi, A; Brusa, L; Fedele, E; Giacomini, P; Lunardi, G; Pierantozzi, M; Stanzione, P | 1 |
| Azulay, JP; Bernhard, G; Giménez-Roldán, S; Markabi, S; Martin, W; Onofrj, M; Schmidt, W; Thomas, A; Vingerhoets, F | 1 |
| Debilly, B; Durif, F; Lees, AJ; Rascol, O; Zijlmans, JC | 1 |
| Bassi, A; Brusa, L; Fedele, E; Lunardi, G; Pasqualetti, P; Peppe, A; Pierantozzi, M; Stanzione, P; Stefani, A | 1 |
| Armenise, E; de Mari, M; Fraddosio, A; Iliceto, G; Lamberti, P; Livrea, P; Zoccolella, S | 1 |
| Guarnieri, M; Hubble, J; Kieburtz, K; Langston, JW; Olanow, CW; Stern, M; Watts, R | 1 |
| Al-Barghouthy, G; Jackson, MJ; Jenner, P; Kuoppamaki, M; Olanow, W; Rose, S; Smith, LA | 1 |
| Clarke, CE; Deane, KH; Spieker, S | 1 |
| Blaha, C; Bremen, D; Gerlach, M; Riederer, P; van den Buuse, M | 1 |
| Boas, J; Hakala, A; Macmahon, D; Myllyla, V; Reichmann, H; Reinikainen, K | 1 |
| Helkamaa, T; Larjonmaa, H; Nissinen, E; Nissinen, H; Rauhala, P; Reenilä, I; Väänänen, A | 1 |
| Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E | 1 |
| Kurlan, R | 1 |
| Comella, C; Widnell, KL | 1 |
| Bronstein, J; Guarnieri, M; Hubble, J; Kang, GA; Ostrem, JL; Rabinowicz, AL; Subramanian, I | 1 |
| Silver, DE | 1 |
| Benetin, J; Blazícek, P; Gmitterová, K; Kukumberg, P; Valkovic, P; Valkovicová, L | 1 |
| Konitsiotis, S | 1 |
| Alvarez, L; Castro, A; Gimenez-Roldan, S; Grandas, F; Hernandez, B; Jenner, P; Linazasoro, G; Luquin, MR; Macias, R; Marin, C; Obeso, JA; Pavon, N; Rodriguez, M; Rodriguez-Oroz, MC; Stochi, F; Tolosa, E; Vaamonde, J; Valldeoriola, F | 1 |
| Agid, Y; Brooks, DJ; Eggert, K; Holopainen, A; Ostergaard, K; Widner, H | 1 |
| Ahlskog, JE; Bower, JH; Josephs, KA; Klos, KJ; Matsumoto, JY | 1 |
| Bremen, D; Erdmann, C; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Brown, LA; Doan, J; Pellis, SM; Suchowersky, O; Whishaw, IQ | 1 |
| Aguilar, E; Marin, C; Obeso, JA | 1 |
| Bremen, D; Erdmann, C; Goetze, O; Muhlack, S; Müller, T; Przuntek, H; Woitalla, D | 1 |
| Camicioli, R; Espay, AJ; Lafontaine, AL; Lang, AE; Martin, WR; Postuma, RB; Ranawaya, R; Suchowersky, O; Zadikoff, C | 1 |
| Stocchi, F | 1 |
| Haapaniemi, T; Hartikainen, P; Heikkinen, H; Jolma, T; Kaakkola, S; Kinnunen, E; Kuopio, AM; Myllylä, V; Nuutinen, J; Rissanen, A; Satomaa, O | 1 |
| Bogomazov, G; Korchounov, A | 1 |
| Kanazawa, I; Kondo, T; Kuno, S; Mizuno, Y; Yamamoto, M; Yanagisawa, N | 1 |
| Henninger, N; Krause, M; Okun, JG; Schwab, S; Wang, Q | 1 |
| Grandas, F; Hernández, B | 1 |
| Barget, M; Debilly, B; Derost, PP; Durif, F; Lemaire, JJ; Llorca, PM; Morand, D; Ouchchane, L; Ulla, M | 1 |
| Di Rocco, A; Werner, P | 1 |
| Lindh, J | 1 |
| Ander, L; Kolf, K; Muhlack, S; Müller, T; Woitalla, D | 1 |
| Angelopoulos, E; Boufidou, F; Evangelopoulos, ME; Kararizou, E; Nikolaou, C; Triantafyllou, NI; Tsounis, S; Vassilopoulos, D | 1 |
| Rezak, M | 1 |
| Hattori, N | 2 |
| Hauser, RA; Schapira, AH; Simonson, W | 1 |
| Armstrong, VW; Bachmann, CG; Guth, N; Happe, S; Helmschmied, K; Paulus, W | 1 |
| Jackson, MJ; Jenner, P; Olanow, W; Rose, S; Smith, LA; Stockwell, KA; Tayarani-Binazir, K; Zubair, M | 1 |
| Pahwa, R | 1 |
| Brooks, DJ; Kuoppamäki, M; Leinonen, M; Nissinen, H | 1 |
| Bareggi, SR; Bet, L; Bondiolotti, G; Meola, G; Pacei, F; Schapira, AH | 1 |
| Dupuis, M; Evrard, F; Jacquerye, P; Muller, T | 1 |
| Erdmann, C; Goetze, O; Müller, T; Woitalla, D | 1 |
| Bourdeix, I; Damier, P; Rerat, K; Viallet, F; Ziegler, M | 1 |
| Benincasa, D; Buttarelli, FR; Giovannelli, M; Pellicano, C; Pontieri, FE; Ruggieri, S | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Aste, R; Cannas, A; Congia, S; Floris, G; Marrosu, MG; Solla, P; Tacconi, P | 1 |
| Fung, VS; Herawati, L; Wan, Y | 1 |
| Jog, M; Panisset, M; Réhel, B; Schecter, R; Suchowersky, O | 1 |
| Hlustik, P; Kanovsky, P; Langova, K; Nevrly, M; Vranova, H | 2 |
| Bourdeix, I; Destée, A; Rérat, K | 1 |
| Abbruzzese, G; Dronamraju, N; Hauser, RA; Kakarieka, A; Mancione, L; Panisset, M | 1 |
| Azulay, T; Brooks, DJ; Giladi, N; Melamed, E; Oertel, W; Poewe, WH; Rascol, O; Stocchi, F; Tal, J; Tolosa, E | 1 |
| Arai, H; Hatta, K; Hattori, N; Ishikawa, K; Kamigaichi, R; Kubo, S; Mochizuki, H; Ogaki, K; Usui, C; Yokoyama, K | 1 |
| Ellmén, J; Hänninen, J; Hartikainen, P; Kaakkola, S; Kaasinen, V; Kailajärvi, M; Korpela, K; Kuoppamäki, M; Löyttyniemi, E; Lyytinen, J; Marttila, R; Ruokoniemi, P | 1 |
| Guarnieri, M; Hubble, JP; Jennings, D; LeWitt, PA; Lyons, KE; Murck, H; Pahwa, R; Rabinowicz, AL; Wang, J | 1 |
| Kuoppamäki, M; Leinonen, M; Nissinen, H; Schapira, AH | 1 |
| Hauser, RA; Seeberger, LC | 1 |
| Muhlack, S; Müller, T | 2 |
| Khan, W; Naz, S; Rana, AQ | 1 |
| Cossu, G; Ferrigno, P; Manca, D; Marcia, E; Melis, M; Molari, A; Murgia, D | 1 |
| Aoki, T; Hamaue, N; Hirafuji, M; Ogata, A; Sasaki, H; Terado, M; Togashi, H; Tsuchida, S; Yabe, I | 1 |
| Amar, K; Eggert, K; Kuoppamäki, M; Leinonen, M; Luotonen, L; Nissinen, H; Oertel, W; Skogar, O | 1 |
| Arstrand, K; Dizdar, N; Kullman, A; Nord, M; Zsigmond, P | 1 |
| Delea, TE; Hagiwara, M; Mancione, L; Thomas, SK | 1 |
| Müller, T | 1 |
| Barone, P; Jankovic, J; Kieburtz, K; Lang, AE; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E | 1 |
| Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N | 1 |
| Almeida, L; Ferreira, JJ; Nunes, T; Poewe, W; Rascol, O; Rocha, JF; Sampaio, C; Soares-da-Silva, P | 1 |
| Armand, C; Groenendaal, H; Tarrants, ML | 1 |
| Kubo, M; Nagai, M; Nishikawa, N; Nomoto, M | 1 |
| Ellmén, J; Kailajärvi, M; Korpela, K; Kuoppamäki, M; Lehtinen, T; Sauramo, A; Vahteristo, M | 1 |
| Barba, E; Bugamelli, F; Marcheselli, C; Raggi, MA | 1 |
| Ferreira, JJ; Sampaio, C | 1 |
| Kaakkola, S | 1 |
| Delea, TE; Hagiwara, M; Thomas, SK | 1 |
| Rascol, O | 1 |
| Agid, Y; Bellanger, A; Ben Djebara, M; Bonnet, AM; Bonnet, C; Charbonnier-Beaupel, F; Corvol, JC; Costentin, J; Fiévet, MH; Hartmann, A; Hulot, JS; Lacomblez, L; Meliksetyan, G; Roze, E; Vidailhet, M; Vrignaud, C; Zahr, N | 1 |
| Aquilonius, SM; Askmark, H; Nyholm, D | 1 |
| Muhlack, S; Müller, T; Woitalla, D | 1 |
| Danoudis, M; Iansek, R | 1 |
| Lew, MF; McCague, K; Somogyi, M; Welsh, M | 1 |
| Rabey, JM; Stocchi, F | 1 |
| Ellmén, J; Ingman, K; Korpela, I; Kuoppamäki, M; Naukkarinen, T; Vahteristo, M | 1 |
| Ishihara, A; Kihira, K; Kimura, Y; Matsumoto, M; Miyachi, T; Nakamura, T; Ohtsuki, T; Yamawaki, T | 1 |
| Askmark, H; Johansson, A; Lennernäs, H; Nyholm, D | 1 |
| Emre, M; Reichmann, H | 1 |
| Bini, V; Bortolato, M; Cannas, A; Marrosu, F; Puligheddu, M; Solla, P | 1 |
| Tarsy, D | 1 |
| Belavic, J | 1 |
| Derkinderen, P; Lebouvier, T; Pouclet, H | 1 |
| Aquilonius, SM; Bäckström, T; Ehrnebo, M; Lewander, T; Nyholm, D; Nyström, C; Panagiotidis, G; Spira, J; Trolin, CG | 1 |
| Brotchie, JM; Fox, SH; Hill, MP; Huot, P; Johnston, TH; Koprich, JB; Snoeren, T | 1 |
| Jančić Stojanović, B; Malenović, A; Stamenković, I; Vemić, A | 1 |
| Arai, M | 1 |
| de Jong, MH; Van Gool, AR; Zemel, D | 1 |
| Calia, K; Graham, DJ; Hsueh, YH; Kelman, JA; Levenson, M; Macurdy, TE; Pinheiro, SP; Shih, D; Williams, JR; Worrall, C | 1 |
| Hernández, B; Martínez-Martín, P; Ricart, J | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Li, Q; Liu, W; Sun, YN; Wang, Y; Yang, JF; Zhang, BS; Zhang, W; Zhao, P | 1 |
| Hernández, B; Kulisevsky, J; Linazasoro, G; López-Lozano, JJ; Marey, J; Mir, P; Tolosa, E | 1 |
| Herrmann, L; Muhlack, S; Müller, T; Salmen, S | 1 |
| Falcão, A; Lopes, N; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P; Vaz-da-Silva, M; Wright, LC | 1 |
| Kiss, LE; Soares-da-Silva, P | 1 |
| Hong, JM; Lee, JS; Lee, PH; Yong, SW; Yoon, JH | 1 |
| Ellmén, J; Kieburtz, K; Kuoppamäki, M; Vahteristo, M | 1 |
| Dillmann, U; Ellenbogen, A; Gupta, S; Hsu, A; Kell, S; Khanna, S; Liang, G; Mahler, A; Rubens, R; Stocchi, F | 1 |
| Bonifácio, MJ; Loureiro, AI; Palma, PN; Soares-da-Silva, P; Torrão, L; Wright, LC | 1 |
| Cardoso, MA; de Carvalho, KA; de Francisco, TM; de Oliveira Vilhena, R; Gasparetto, JC; Guimarães de Francisco, TM; Martins, CA; Pontarolo, R; Ribeiro, RP | 1 |
| Aho, V; Christopher, S; Ellmén, J; Haukka, J; Hoti, F; Korhonen, P; Kuoppamäki, M; Prami, T; Pukkala, E; Vahteristo, M | 1 |
| Cao, ZH; Chen, HX; Ding, ZG; Song, JH; Zhang, GB; Zhou, PY | 1 |
| Kuoppamäki, M; Leinonen, M; Poewe, W | 1 |
| Elmer, L; Gil, RA; Gupta, S; Hsu, A; Kell, S; Khanna, S; Modi, NB; Nausieda, PA; Rubens, R; Singer, C; Spiegel, J | 1 |
| Abe, H; Ebihara, K; Ikarashi, Y; Imamura, S; Ishida, Y; Kase, Y; Koganemaru, G; Mizoguchi, K; Sekiguchi, K; Tabuchi, M | 1 |
| Ferreira, JJ; Lees, A; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P | 1 |
| Bedi, G; Bisaga, A; Foltin, RW; Nunes, EV; Shiffrin, L; Vadhan, NP | 1 |
| Baek, JS; Choo, CC; Loo, SC; Qian, C; Shen, Z; Tan, NS | 1 |
| Asanuma, M; Miyazaki, I | 1 |
| Comoglu, SS; Guven, H; Kocer, B | 1 |
| Abdel-Ghany, MF; Ayad, MF; Hussein, LA; Youssef, MM | 1 |
| Fox, SH; Freitas, ME; Ruiz-Lopez, M | 1 |
| Nielsen, EI; Nyholm, D; Senek, M | 2 |
| Altamura, C; Basile, S; Calcagno, M; Garibaldi, S; Pinelli, S; Salerno, MG | 1 |
| Klein, S; Wollmer, E | 1 |
| Chen, J; Li, J; Liu, X; Lou, Z; Sun, Y | 1 |
| Katsaiti, I; Nixon, J | 1 |
| Ferreira, JJ; Keller, B; Lees, AJ; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P | 1 |
| Baek, JS; Ho, HK; Lim, KL; Loo, SCJ; Pang, YY; Tan, EY; Tee, JK | 1 |
| Alaa, H; Belal, F; Ibrahim, F; Sheribah, ZA | 1 |
| Čierny, D; Grofik, M; Kurča, E; Michalik, J; Nosáľ, V; Sivák, Š; Tatarková, Z; Turčanová Koprušáková, M | 1 |
| Metzer, WS; Rodrigues, FB | 1 |
| Di Vico, IA; Novelli, A; Ramat, S; Sorbi, S; Terenzi, F | 1 |
| Asano, AGC; Asano, NMJ; de Souza, PRE; Dos Santos, EUD; Duarte, EBC; Maia, MMD; Miranda, LMR | 1 |
| Klivényi, P; Salamon, A; Szpisjak, L; Vécsei, L; Zádori, D | 2 |
| Arkadir, D; Bergman, H; Eitan, R; Hajyahya, A; Israel, Z; Linetsky, E; Snineh, MA | 1 |
| Li, K; Li, S; Liao, X; Liu, D; Shuai, B; Wu, N | 1 |
| Burmaoğlu, RE; Sağlık Aslan, S | 1 |
| García Ruiz-Espiga, P; Linazasoro-Cristóbal, G; López Del Val, LJ; López-Manzanares, L; Luquin-Piudo, MR; Martínez-Castrillo, JC; Mir, P; Pagonabarraga-Mora, J | 1 |
| Anamnart, C; Kitjarak, R | 1 |
| Ishii, K; Nakamagoe, K; Tamaoka, A; Tsuji, H | 1 |
| Conrad, R; Fois, AF; Hampe, T | 1 |
| Adar, L; Caraco, Y; Case, R; Djaldetti, R; Giladi, N; Gurevich, T; Leibman-Barak, S; Sasson, N | 1 |
| Habet, S | 1 |
| Fu, SC; Hsieh, YC; Lee, CH; Lin, SH; Wang, H; Wu, PH | 1 |
| Müller, T; Schlegel, E; Thiede, HM; Zingler, S | 1 |
| Bernstein, M; Hsieh, E; Juurlink, DN; Rodrigues, DM | 1 |
| Ellmén, J; Kuoppamäki, M; Rouru, J; Sjöstedt, N; Tuunainen, J; Vahteristo, M; Yliperttula, M | 1 |
| Langer, K; Rose, O; Weitzel, J; Wünsch, A | 1 |
| Baló, B; Botz, K; Györfi, B; Jost, WH | 1 |
| Jost, WH | 2 |
| Aureli, F; Cortelli, P; Leta, V; Metta, V; Ray Chaudhuri, K; Rizos, A; Rodriguez-Blazquez, C; Trivedi, D; van Wamelen, DJ | 1 |
| Castilla-Fernández, G; Chaudhuri, KR; Di Foggia, V; Harrison-Jones, G; Marston, XL; Morgante, F | 1 |
| Antonini, A; D'Onofrio, V; Guerra, A | 1 |
48 review(s) available for levodopa and entacapone
| Article | Year |
|---|---|
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
Topics: Animals; Behavior, Animal; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catecholamines; Catechols; Dihydroxyphenylalanine; Humans; Levodopa; Microdialysis; Nitriles; Nitrophenols; Pentanones; Tolcapone; Tomography, Emission-Computed | 1994 |
COMT inhibition: a new treatment strategy for Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Psychomotor Performance; Randomized Controlled Trials as Topic; Tolcapone | 1998 |
Extending levodopa action: COMT inhibition.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Pentanones; Tolcapone | 1998 |
COMT inhibition in the treatment of Parkinson's disease.
Topics: Benzophenones; Catechol O-Methyltransferase; Catechols; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease | 1999 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease, Secondary; Propranolol; Randomized Controlled Trials as Topic; Selegiline; Tolcapone | 1999 |
Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Patient Selection; Tolcapone | 2000 |
The role of entacapone in the management of Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Placebos | 2000 |
Issues important for rational COMT inhibition.
Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2000 |
Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.
Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinsonian Disorders; Tolcapone | 2000 |
Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.
Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Dopamine Agents; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2001 |
Entacapone in the management of Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catecholamines; Catechols; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2002 |
Position of COMT inhibition in the treatment of Parkinson's disease.
Topics: Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease; Risk Assessment | 2003 |
Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2003 |
Entacapone/levodopa/carbidopa combination tablet: Stalevo.
Topics: Administration, Oral; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Drug Combinations; Humans; Levodopa; Movement Disorders; Nitriles; Parkinson Disease; Tablets | 2003 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Nitriles; Parkinson Disease, Secondary; Primates; Rats | 2004 |
Continuous dopaminergic stimulation in early and advanced Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechols; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2004 |
Clinical advantages of COMT inhibition with entacapone - a review.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease; Quality of Life | 2004 |
Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2004 |
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2005 |
Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2004 |
Novel pharmacological strategies for motor complications in Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Indans; Levodopa; Liposomes; Monoamine Oxidase Inhibitors; Motor Neurons; Movement Disorders; Nitriles; Parkinson Disease; Receptors, Glutamate; Signal Transduction | 2005 |
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Topics: Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine; Drug Therapy, Combination; Humans; Hyperhomocysteinemia; Levodopa; MPTP Poisoning; Neuroprotective Agents; Nitriles; Parkinson Disease; Parkinsonian Disorders; Rats; Treatment Outcome | 2005 |
The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Delayed-Action Preparations; Dopa Decarboxylase; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2006 |
Long-term care of Parkinson's disease. Strategies for managing "wearing off" symptom re-emergence and dyskinesias.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Nitriles; Parkinson Disease | 2006 |
Current pharmacotherapeutic treatment options in Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Parkinson Disease; Receptors, N-Methyl-D-Aspartate | 2007 |
[Neuromuscular disorders due to adverse effects of antiparkinson agents].
Topics: Amantadine; Antiparkinson Agents; Catechols; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuromuscular Diseases; Nitriles; Trihexyphenidyl | 2007 |
Role of the pharmacist in the effective management of wearing-off in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Parkinson Disease; Patient Education as Topic; Pharmacists; Professional Role; Severity of Illness Index | 2007 |
Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Topics: Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2006 |
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Catechols; Clinical Trials, Phase III as Topic; Dopa Decarboxylase; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Time; Treatment Outcome | 2008 |
Entacapone.
Topics: Animals; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Parkinson Disease | 2010 |
Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2010 |
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Topics: Animals; Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dopamine Agonists; Drug Delivery Systems; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2011 |
Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
[Programs for continuing medical education: a session: 4. The pathogenesis and update for the treatments of Parkinson's disease].
Topics: Benserazide; Benzothiazoles; Catechols; Circadian Rhythm; Dementia; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Dyskinesias; Education, Medical, Continuing; Hallucinations; Humans; Levodopa; Nitriles; Parkinson Disease; Practice Guidelines as Topic; Pramipexole; Reference Standards; Referral and Consultation | 2014 |
Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Catechols; Dopamine Agonists; Drug Administration Schedule; Drug Combinations; Hospitalization; Humans; Levodopa; Monoamine Oxidase Inhibitors; Nitriles; Nursing Care; Parkinson Disease | 2014 |
Pooled analysis of phase III with entacapone in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Clinical Trials, Phase III as Topic; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies; Selegiline | 2014 |
Novel Levodopa Formulations for Parkinson's Disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Chemistry, Pharmaceutical; Drug Combinations; Humans; Levodopa; Nitriles; Parkinson Disease | 2016 |
Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2017 |
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease; Tolcapone; Treatment Outcome | 2018 |
Opicapone for the treatment of Parkinson's disease: an update.
Topics: Administration, Oral; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease | 2019 |
Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Humans; Levodopa; Nitriles; Parkinson Disease | 2020 |
Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Dopamine Agonists; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease; Patient Selection; Treatment Outcome | 2020 |
Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime.
Topics: Antiparkinson Agents; Catechols; Drug Combinations; Humans; Levodopa; Motor Activity; Nitriles; Parkinson Disease; Quality of Life; Randomized Controlled Trials as Topic; Tablets | 2020 |
[Triple combination of levodopa, carbidopa and entacapone by intrajejunal pump in advanced Parkinson's disease].
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Observational Studies as Topic; Parkinson Disease | 2022 |
Current and novel infusion therapies for patients with Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease | 2023 |
82 trial(s) available for levodopa and entacapone
| Article | Year |
|---|---|
The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
Topics: Aged; Brain; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dihydroxyphenylalanine; Drug Synergism; Female; Fluorine Radioisotopes; Humans; Levodopa; Male; Middle Aged; Nitriles; Occipital Lobe; Parkinson Disease; Tomography, Emission-Computed | 1994 |
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
Topics: Aged; Blood Pressure; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Hemodynamics; Homovanillic Acid; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Pulse; Respiration | 1993 |
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
Topics: Aged; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Psychomotor Performance; Treatment Outcome | 1994 |
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
Topics: Aged; Catechol O-Methyltransferase Inhibitors; Catechols; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 1994 |
Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients.
Topics: Adult; Aged; Biological Availability; Catechol O-Methyltransferase Inhibitors; Catechols; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 1994 |
Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations.
Topics: Aged; Antiparkinson Agents; Biological Availability; Catechols; Cross-Over Studies; Double-Blind Method; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Levodopa; Middle Aged; Motor Activity; Nitriles; Parkinson Disease | 1996 |
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
Topics: Adult; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Humans; Levodopa; Male; Nitriles; Reference Values | 1995 |
Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agents; Double-Blind Method; Enzyme Inhibitors; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 1996 |
A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease.
Topics: Aged; Catechols; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 1996 |
COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.
Topics: Adult; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Dopamine; Double-Blind Method; Enzyme Inhibitors; Human Growth Hormone; Humans; Levodopa; Male; Nitriles; Placebos; Prolactin; Tyrosine | 1996 |
Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Benserazide; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Nitriles; Parkinson Disease; Selegiline | 1997 |
Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.
Topics: Aged; Antiparkinson Agents; Catechols; Double-Blind Method; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Movement; Nitriles; Parkinson Disease; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome | 1997 |
Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
Topics: Aged; Antiparkinson Agents; Catechols; Cross-Over Studies; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 1998 |
Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease | 1998 |
Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Topics: Adult; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Interactions; Enzyme Inhibitors; Erythrocytes; Humans; Levodopa; Male; Nitriles | 1999 |
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2000 |
Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome | 2001 |
Twelve-month safety of entacapone in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Disability Evaluation; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Safety; Time Factors | 2001 |
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Topics: Aged; Antiparkinson Agents; Austria; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Germany; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome | 2002 |
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
Topics: Aged; Antiparkinson Agents; Catechols; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Levodopa; Markov Chains; Nitriles; Parkinson Disease; Patient Satisfaction; Quality-Adjusted Life Years; Treatment Outcome; United States | 2002 |
Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
Topics: Adult; Analysis of Variance; Antiparkinson Agents; Biological Availability; Catechols; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Male; Nitriles | 2002 |
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
Topics: Aged; Catechols; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies | 2003 |
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Neurologic Examination; Nitriles; Parkinson Disease | 2003 |
Levodopa/carbidopa/entacapone (Stalevo).
Topics: Aged; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechols; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Evaluation; Female; Headache; Humans; Levodopa; Male; Middle Aged; Nausea; Nitriles; Reference Values; Therapeutic Equivalency | 2004 |
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients.
Topics: Aged; Area Under Curve; Carbidopa; Catechols; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Single-Blind Method | 2004 |
The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Hemodynamics; Humans; Levodopa; Male; Middle Aged; Nitriles; Norepinephrine; Oxygen Consumption; Parkinson Disease; Pulmonary Gas Exchange; Respiratory Mechanics | 2002 |
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Single-Blind Method; Treatment Outcome | 2004 |
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
Topics: Antiparkinson Agents; Apomorphine; Catechols; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease | 2004 |
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Drug Resistance; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2004 |
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Case-Control Studies; Catechols; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Folic Acid; Homocysteine; Humans; Levodopa; Linear Models; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12 | 2005 |
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome | 2004 |
Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Quality of Life | 2005 |
The effect of entacapone on homocysteine levels in Parkinson disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cohort Studies; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Treatment Outcome | 2005 |
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Disability Evaluation; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Pain Measurement; Parkinson Disease; Quality of Life; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome | 2005 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
Motor deficits in Parkinsonian reaching: dopa-sensitivity influenced by real-world task constraint.
Topics: Activities of Daily Living; Aged; Amantadine; Antiparkinson Agents; Arm; Benzothiazoles; Biomechanical Phenomena; Carbidopa; Catechols; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Movement; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 2006 |
Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Tyrosine | 2006 |
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Topics: Aged; Antiparkinson Agents; Canada; Catechols; Double-Blind Method; Drug Combinations; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Placebo Effect; Treatment Outcome; United States; Vitamin B 12; Vitamins | 2006 |
Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
Topics: Adult; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Satisfaction; Treatment Outcome | 2006 |
Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.
Topics: Absenteeism; Antiparkinson Agents; Catechols; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Employment; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Self Concept | 2006 |
Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Catechols; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2007 |
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.
Topics: Aged; Antiparkinson Agents; Catechols; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Early Diagnosis; Female; Humans; Interviews as Topic; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Compliance; Patient Satisfaction; Prospective Studies; Quality of Life; Time; Time Factors; Treatment Outcome | 2007 |
Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechols; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2007 |
The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Catechols; Female; Folic Acid; Humans; Immunoassay; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12 | 2007 |
Bimodal administration of entacapone in Parkinson's disease patients improves motor control.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Catechol O-Methyltransferase; Catechols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Nitriles; Parkinson Disease; Severity of Illness Index | 2008 |
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Breath Tests; Caprylates; Carbidopa; Carbon Isotopes; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastric Emptying; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Solubility | 2008 |
Entacapone in elderly Parkinsonian patients experiencing levodopa-related wearing-off: a pilot study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Pilot Projects | 2009 |
Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome | 2009 |
Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Canada; Catechols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Surveys and Questionnaires; Treatment Outcome | 2008 |
Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2009 |
Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechols; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2009 |
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index | 2009 |
Validation of the freezing of gait questionnaire in patients with Parkinson's disease.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Catechols; Double-Blind Method; Female; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Nitriles; Parkinson Disease; Principal Component Analysis; Psychiatric Status Rating Scales; Reproducibility of Results; Severity of Illness Index; Statistics as Topic; Surveys and Questionnaires | 2009 |
Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
Topics: Administration, Oral; Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Carbidopa; Case-Control Studies; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Nitriles; Young Adult | 2009 |
Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors | 2009 |
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Topics: Aged; Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Drug-Related Side Effects and Adverse Reactions; Dyskinesias; Feasibility Studies; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2010 |
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Risk; Time Factors; Treatment Outcome | 2010 |
A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.
Topics: Acetophenones; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Endpoint Determination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome | 2010 |
Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.
Topics: Adolescent; Adult; Antiparkinson Agents; Area Under Curve; Biological Availability; Carbidopa; Catechols; Cross-Over Studies; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Female; Half-Life; Humans; Levodopa; Male; Nitriles; Time Factors; Young Adult | 2010 |
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Topics: Aged; Antiparkinson Agents; Biological Availability; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Genotype; Humans; Levodopa; Male; Methionine; Middle Aged; Nitriles; Parkinson Disease; Pharmacogenetics; Polymorphism, Genetic; Valine | 2011 |
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Combinations; Drug Therapy, Combination; Female; Half-Life; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2011 |
A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesias; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Single-Blind Method | 2011 |
Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies; Quality of Life; Single-Blind Method | 2011 |
Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dysarthria; Facial Expression; Female; Humans; Hypokinesia; Indans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Motor Activity; Muscle Rigidity; Nitriles; Parkinson Disease; Severity of Illness Index; Tremor | 2011 |
The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.
Topics: Adult; Antiparkinson Agents; Area Under Curve; Carbidopa; Catechols; Cross-Over Studies; Dopamine Agents; Drug Combinations; Drug Interactions; Female; Humans; Levodopa; Male; Nitriles; Young Adult | 2012 |
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechols; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Pilot Projects; Self Report; Single-Blind Method; Sweden; Tolcapone; Tyrosine | 2012 |
Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers.
Topics: Adult; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Levodopa; Male; Nitriles; Tablets; Young Adult | 2013 |
Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.
Topics: Aged; Arginine Vasopressin; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Humans; Inappropriate ADH Syndrome; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2012 |
Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cardiovascular Diseases; Catechols; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease; Risk; Treatment Outcome | 2013 |
Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires | 2014 |
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Topics: Adult; Antiparkinson Agents; Area Under Curve; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Oxadiazoles; Young Adult | 2014 |
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Treatment Outcome; Walking | 2014 |
Rhythmic auditory stimulation with visual stimuli on motor and balance function of patients with Parkinson's disease.
Topics: Acoustic Stimulation; Aged; Benserazide; Benzothiazoles; Catechols; Dose-Response Relationship, Drug; Drug Combinations; Female; Gait; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Periodicity; Piribedil; Postural Balance; Pramipexole; Walking | 2015 |
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Treatment Outcome | 2015 |
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Treatment Outcome | 2015 |
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Europe; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Oxadiazoles; Parkinson Disease | 2016 |
Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
Topics: Adult; Aged; Aged, 80 and over; Catechol O-Methyltransferase; Catechols; Dopamine Agonists; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies | 2016 |
Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Over Studies; Drug Combinations; Female; Humans; Infusions, Parenteral; Levodopa; Male; Nitriles; Parkinson Disease; Treatment Outcome | 2017 |
Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
Topics: Carbidopa; Catechol O-Methyltransferase; Catechols; Cross-Over Studies; Dopa Decarboxylase; Double-Blind Method; Drug Combinations; Drug Delivery Systems; Female; Gels; Genotype; Humans; Levodopa; Male; Models, Biological; Nitriles; Parkinson Disease; Polymorphism, Genetic | 2020 |
Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Research Design; Vitamin B 12 | 2021 |
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.
Topics: Administration, Oral; Aged; Antiparkinson Agents; Carbidopa; Catechols; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Infusions, Subcutaneous; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Proof of Concept Study; Treatment Outcome | 2021 |
Effect of Carbidopa Dose on Levodopa Pharmacokinetics With and Without Catechol-O-Methyltransferase Inhibition in Healthy Subjects.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Healthy Volunteers; Humans; Levodopa; Parkinson Disease | 2023 |
130 other study(ies) available for levodopa and entacapone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
Topics: Drug Repositioning; Gastrointestinal Microbiome; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Validation Studies as Topic | 2021 |
Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
Topics: Amidines; Animals; Benzophenones; Biogenic Monoamines; Brain; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Homovanillic Acid; Hypothalamus; Levodopa; Male; Methyldopa; Nitriles; Nitrophenols; Pyridones; Rats; Rats, Inbred Strains; Tolcapone | 1992 |
Acute toxicity of three new selective COMT inhibitors in mice with special emphasis on interactions with drugs increasing catecholaminergic neurotransmission.
Topics: Amphetamine; Animals; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catecholamines; Catechols; Clorgyline; Convulsants; Desipramine; Drug Interactions; Lethal Dose 50; Levodopa; Male; Mice; Motor Activity; Nitriles; Nomifensine; Pentanones; Selegiline; Synaptic Transmission; Yohimbine | 1991 |
Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Catechols; Levodopa; Macaca fascicularis; Male; Nitriles; Parkinson Disease; Pentanones; Tyrosine | 1991 |
Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amidines; Animals; Biogenic Monoamines; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Microdialysis; Neostriatum; Nitriles; Pyridones; Rats; Rats, Wistar; Stereotaxic Techniques; Tryptophan; Tyrosine | 1994 |
Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
Topics: Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Depression; Desipramine; Dihydroxyphenylalanine; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Levodopa; Male; Motor Activity; Nitriles; Nitrophenols; Rats; Rats, Wistar; Swimming; Tolcapone | 1995 |
The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study.
Topics: Animals; Carbidopa; Catechols; Dogs; Extracellular Space; Levodopa; Male; Microdialysis; Muscle, Skeletal; Nitriles; Premedication | 1995 |
Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats.
Topics: Amidines; Amphetamine; Animals; Behavior, Animal; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Clorgyline; Drug Interactions; Drug Synergism; Levodopa; Male; Methylation; Nitriles; Nitrophenols; Pyridones; Rats; Rats, Wistar; Tolcapone | 1993 |
Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
Topics: Animals; Catechols; Corpus Striatum; Dihydroxyphenylalanine; Fluorine Radioisotopes; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Nitriles; Parkinson Disease; Tomography, Emission-Computed | 1993 |
The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Electrocardiography; Half-Life; Homovanillic Acid; Humans; Levodopa; Male; Nitriles; Reference Values; Tyrosine | 1993 |
Catechol-O-methyltransferase inhibition increases the uptake of 11C-3-(3,4-dihydroxyphenyl)-L-alanine in the rat pancreas.
Topics: Analysis of Variance; Animals; Benzophenones; Catechol O-Methyltransferase; Catechols; Chromatography, High Pressure Liquid; Culture Techniques; Drug Interactions; Enzyme Inhibitors; Injections, Intravenous; Levodopa; Male; Nitriles; Pancreas; Radioactive Tracers; Rats; Rats, Sprague-Dawley; Tomography, Emission-Computed | 1996 |
Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Homovanillic Acid; Levodopa; Liver; Male; Nitriles; Rats; Rats, Sprague-Dawley | 1997 |
Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.
Topics: Amidines; Animals; Antiparkinson Agents; Benzophenones; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Female; Levodopa; Macaca mulatta; Motor Activity; Nitriles; Nitrophenols; Parkinson Disease; Pregnancy; Pyridones; Rats; Tolcapone | 1998 |
Catechol O-methyltransferase inhibition and the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Blood-Brain Barrier; Brain; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Intestinal Absorption; Levodopa; Nitriles; Parkinson Disease; Tissue Distribution | 1998 |
Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Carbidopa; Catechols; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Levodopa; Male; Movement Disorders; Nitriles; Severity of Illness Index | 1997 |
Conditioned place preference induced by a combination of L-dopa and a COMT inhibitor, entacapone, in rats.
Topics: Animals; Catechol O-Methyltransferase Inhibitors; Catechols; Conditioning, Psychological; Corpus Striatum; Dopamine; Drug Synergism; Enzyme Inhibitors; Levodopa; Limbic System; Male; Nitriles; Rats; Rats, Wistar; Reinforcement, Psychology; Synapses | 1998 |
Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 1998 |
[COMT inhibitors].
Topics: Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 1999 |
Several classes of new drugs emerging for Parkinson disease.
Topics: Antiparkinson Agents; Benzothiazoles; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Enzyme Inhibitors; Humans; Indoles; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Thiazoles | 1999 |
Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA.
Topics: Animals; Autoradiography; Brain; Brain Chemistry; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Macaca fascicularis; Male; Nitriles; Oligonucleotide Probes; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins | 2000 |
Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
Topics: Aged; Antiparkinson Agents; Brain; Catechol O-Methyltransferase; Catechols; Dihydroxyphenylalanine; Female; Humans; Levodopa; Male; Middle Aged; Movement; Nitriles; Parkinson Disease; Time Factors; Tomography, Emission-Computed | 2001 |
[Dopaminergic agonists in the treatment of Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Benzothiazoles; Biological Availability; Bromocriptine; Catechols; Dopamine Agonists; Drug Combinations; Drug Hypersensitivity; Humans; Hypotension, Orthostatic; Indoles; Levodopa; Metabolic Clearance Rate; Nitriles; Parkinson Disease; Pergolide; Pramipexole; Selegiline; Thiazoles | 2000 |
[Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
Topics: Aged; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine; Drug Therapy, Combination; Dyskinesias; Humans; Levodopa; Nitriles; Parkinson Disease | 2001 |
[Parkinson's disease].
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Catechols; Depressive Disorder; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Follow-Up Studies; Humans; Indoles; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nitriles; Parkinson Disease; Parkinsonian Disorders; Pergolide; Psychiatric Status Rating Scales; Psychotic Disorders; Time Factors | 2001 |
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hydroxyl Radical; Levodopa; Male; Microdialysis; Nitriles; Nitrophenols; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Wistar; Tolcapone | 2001 |
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Benzophenones; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Substance Withdrawal Syndrome; Tolcapone | 2001 |
Current advances in Parkinson's disease.
Topics: Antidepressive Agents; Antiparkinson Agents; Benzothiazoles; Brain Stem; Catechols; Depression; Dopamine Agonists; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles | 2001 |
Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Topics: Animals; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cerebral Cortex; Corpus Striatum; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Levodopa; Macaca fascicularis; Mazindol; Neural Pathways; Nitriles; Oxidative Stress; Reference Values; RNA, Messenger; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |
Design and synthesis of a novel L-dopa-entacapone codrug.
Topics: Animals; Antiparkinson Agents; Carbamates; Catechols; Half-Life; Humans; Kinetics; Levodopa; Nitriles; Rabbits | 2002 |
Entacapone in restless legs syndrome.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Delayed-Action Preparations; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Middle Aged; Neurologic Examination; Nitriles; Restless Legs Syndrome | 2002 |
Effects of entacapone and tolcapone on mitochondrial membrane potential.
Topics: Animals; Benzophenones; Catechols; Levodopa; Male; Membrane Potentials; Mitochondria, Liver; Nitriles; Nitrophenols; Rats; Rats, Sprague-Dawley; Tolcapone | 2002 |
The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Treatment Outcome | 2003 |
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Nitriles; Parkinsonian Disorders; Pulse Therapy, Drug; Substantia Nigra; Time Factors | 2003 |
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Benzophenones; Blood Platelets; Catechols; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinson Disease; Retrospective Studies; Sex Characteristics; Tolcapone; Tyrosine; Up-Regulation | 2003 |
Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Catechols; Confidence Intervals; Drug Therapy, Combination; Female; Humans; Internationality; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Prospective Studies | 2003 |
The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience.
Topics: Antiparkinson Agents; Catechols; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Motor Activity; Neurologic Examination; Nitriles; Parkinson Disease; Prospective Studies; Time Factors | 2003 |
Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor.
Topics: Catechols; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Half-Life; Humans; Levodopa; Nitriles; Parkinson Disease; Time Factors | 2003 |
The value of post-marketing medication surveys in Parkinson's disease.
Topics: Catechols; Humans; Levodopa; Nitriles; Parkinson Disease; Product Surveillance, Postmarketing | 2004 |
Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechols; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Satisfaction; Product Surveillance, Postmarketing; Quality of Life; Treatment Outcome | 2004 |
Stalevo for Parkinson's disease.
Topics: Carbidopa; Catechols; Diarrhea; Dose-Response Relationship, Drug; Drug Combinations; Humans; Levodopa; Nausea; Nitriles; Parkinson Disease | 2004 |
[Treatment in Parkinson disease].
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Cholinergic Antagonists; Dopamine Agonists; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2004 |
Role of entacapone in later Parkinson's disease not yet established.
Topics: Antiparkinson Agents; Catechols; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2004 |
Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Catechols; Disability Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Surveys and Questionnaires | 2004 |
Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Subcutaneous; Levodopa; Locomotion; Male; MPTP Poisoning; Nitriles; Severity of Illness Index; Substantia Nigra; Time Factors | 2005 |
Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Catechols; Corpus Striatum; Dopamine; Drug Synergism; Levodopa; Male; Nitriles; Oxidopamine; Rats; Rats, Sprague-Dawley | 2004 |
The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Homocysteine; Hyperhomocysteinemia; Levodopa; Male; Nitriles; Rats; Rats, Wistar | 2005 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2005 |
Improving quality of life in early Parkinson's.
Topics: Aged; Antiparkinson Agents; Catechols; Drug Synergism; Humans; Levodopa; Nitriles; Parkinson Disease; Quality of Life | 2005 |
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Iatrogenic Disease; Indoles; Levodopa; Male; Middle Aged; Neurology; Neuropharmacology; Neurotoxicity Syndromes; Nitriles; Parkinson Disease; Pramipexole; Selegiline; Thiazoles; Treatment Outcome | 2005 |
Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cross-Sectional Studies; Drug Therapy, Combination; Enzyme Inhibitors; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Vitamin B 12 | 2005 |
Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Catechols; Databases, Factual; Dopamine Agonists; Humans; Indoles; Levodopa; Male; Mental Disorders; Middle Aged; Multiple System Atrophy; Nitriles; Parkinson Disease; Pramipexole; Sexual Dysfunctions, Psychological; Thiazoles | 2005 |
Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2006 |
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors | 2006 |
Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats.
Topics: Analgesics, Non-Narcotic; Analysis of Variance; Animals; Catechols; Drug Interactions; Enzyme Inhibitors; Homocysteine; Hyperhomocysteinemia; Immunoassay; Levodopa; Male; Nitriles; Nitrous Oxide; Random Allocation; Rats; Rats, Wistar | 2007 |
Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?
Topics: Activities of Daily Living; Age Factors; Aged; Antiparkinson Agents; Bipolar Disorder; Catechols; Cognition; Combined Modality Therapy; Communication; Deep Brain Stimulation; Dysarthria; Electrodes, Implanted; Emotions; Female; Humans; Levodopa; Male; Middle Aged; Movement; Neuropsychological Tests; Nitriles; Parkinson Disease; Pergolide; Prejudice; Quality of Life; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome; Weight Gain | 2007 |
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Topics: Antiparkinson Agents; Carbon; Catechol O-Methyltransferase Inhibitors; Catechols; Folic Acid; Humans; Hyperhomocysteinemia; Levodopa; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; S-Adenosylmethionine; Time Factors; Vitamin B 12; Vitamin B 6 | 2007 |
Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine.
Topics: Adolescent; Antiparkinson Agents; Bromocriptine; Catechols; Drug Therapy, Combination; Epilepsy; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pregnancy; Prenatal Exposure Delayed Effects | 2007 |
Homocysteine in restless legs syndrome.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Reference Values; Restless Legs Syndrome; Vitamin B 12; Vitamin B 6 | 2008 |
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Catechols; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Drug Synergism; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Activity; Nitriles | 2007 |
[Isolated pulmonary hypertension and pergolide].
Topics: Antiparkinson Agents; Benserazide; Benzothiazoles; Blood Pressure; Catechols; Dyspnea; Echocardiography; Humans; Hypertension, Pulmonary; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease, Postencephalitic; Pergolide; Pramipexole | 2008 |
Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechols; Dopa Decarboxylase; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; France; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Practice Patterns, Physicians'; Retrospective Studies | 2008 |
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Catechols; Corpus Striatum; Dynorphins; Electron Transport Complex IV; Enkephalins; Gene Expression; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Nitriles; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Subthalamus | 2008 |
Levodopa/carbidopa/entacapone-induced acute Pisa syndrome in a Parkinson's disease patient.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dystonic Disorders; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Tropanes | 2008 |
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
Topics: Aged; Antiparkinson Agents; Azepines; Benzothiazoles; Cabergoline; Carbidopa; Catatonia; Catechols; Drug Therapy, Combination; Electroconvulsive Therapy; Ergolines; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2009 |
Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Catechols; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Retrospective Studies | 2009 |
Levodopa/carbidopa/entacapone in Parkinson's disease.
Topics: Antiparkinson Agents; Biological Availability; Carbidopa; Catechols; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease | 2009 |
Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Delayed-Action Preparations; Dihydroxyphenylalanine; Enzyme Inhibitors; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors; Tyrosine | 2009 |
Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.
Topics: Antiparkinson Agents; Catechols; Drug Resistance; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Respiratory Mechanics; Respiratory Tract Diseases | 2009 |
Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.
Topics: Aged; Antiparkinson Agents; Catechols; Encephalitis; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Peripheral Nervous System Diseases | 2009 |
Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dopa Decarboxylase; Dopamine; Drug Combinations; Drug Synergism; Encephalitis Virus, Japanese; Encephalitis, Japanese; Enzyme Inhibitors; Levodopa; Nitriles; Parkinsonian Disorders; Rats; Rats, Inbred F344; Treatment Outcome | 2010 |
The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Area Under Curve; Catechols; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Mepivacaine; Microdialysis; Middle Aged; Nitriles; Parkinson Disease; Time Factors | 2010 |
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Carbidopa; Catechols; Cohort Studies; Dosage Forms; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Patient Compliance; Retrospective Studies; Tablets | 2010 |
Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Time Factors | 2010 |
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Schizophrenia, Paranoid; Syndrome | 2010 |
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans; Levodopa; Markov Chains; Models, Economic; Nitriles; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States | 2010 |
Fluctuation in plasma entacapone concentrations in accordance with variable plasma levodopa concentrations.
Topics: Adult; Antiparkinson Agents; Area Under Curve; Catechols; Drug Therapy, Combination; Humans; Levodopa; Male; Nitriles; Parkinson Disease | 2010 |
Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.
Topics: Antiparkinson Agents; Calibration; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Drug Combinations; Humans; Levodopa; Methyldopa; Nitriles; Reproducibility of Results; Solid Phase Extraction | 2011 |
Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Nitriles; Parkinson Disease; Randomized Controlled Trials as Topic; Receptors, Dopamine | 2010 |
The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cohort Studies; Delivery of Health Care; Health Care Costs; Humans; Levodopa; Nitriles; Parkinson Disease; Patient Compliance; Retrospective Studies | 2011 |
Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint.
Topics: Antiparkinson Agents; Catechols; Dyskinesia, Drug-Induced; Humans; Levodopa; Nitriles; Parkinson Disease | 2011 |
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Biomarkers; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopa Decarboxylase; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Japan; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome; Tyrosine | 2011 |
Finasteride attenuates pathological gambling in patients with Parkinson disease.
Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Catechols; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Ergolines; Finasteride; Gambling; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Treatment Outcome; Video Games | 2012 |
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Subthalamus | 2012 |
Drugs for treating Parkinson disease.
Topics: Antiparkinson Agents; Apomorphine; Carbidopa; Catechols; Drug Combinations; Drugs, Generic; Humans; Indans; Levodopa; Nitriles; Parkinson Disease | 2012 |
Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Dyskinesia, Drug-Induced; Dystonia; Female; Foot Diseases; Humans; Levodopa; Middle Aged; Neurologic Examination; Nitriles; Parkinson Disease | 2013 |
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.
Topics: Animals; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Nitriles | 2013 |
Chaotropic agents in liquid chromatographic method development for the simultaneous analysis of levodopa, carbidopa, entacapone and their impurities.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Chromatography, Reverse-Phase; Drug Contamination; Levodopa; Nitriles; Particle Size; Reproducibility of Results; Sensitivity and Specificity; Trifluoroacetic Acid | 2013 |
Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Carbidopa; Catechols; Clozapine; Diagnosis, Differential; Fluphenazine; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Schizophrenia; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2014 |
Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Cross-Sectional Studies; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Retrospective Studies; Socioeconomic Factors; Spain | 2014 |
[Effects of entacapone on plasma homocysteine in Parkinson's disease patients on levodopa].
Topics: Aged; Catechols; Cross-Sectional Studies; Female; Homocysteine; Humans; Levodopa; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Nitriles; Parkinson Disease | 2013 |
Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Chromatography, Reverse-Phase; Cysteine; Dipeptides; Drug Delivery Systems; Female; Humans; Levodopa; Male; Methyldopa; Middle Aged; Nitriles; Parkinson Disease; Time Factors | 2014 |
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Nitrophenols; Parkinson Disease; Psychomotor Performance; Statistics, Nonparametric; Tolcapone; Treatment Outcome | 2014 |
Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.
Topics: Acetophenones; Animals; Catalysis; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Clinical Trials as Topic; Crystallography, X-Ray; Humans; Inhibitory Concentration 50; Levodopa; Male; Models, Molecular; Nitriles; Oxadiazoles; Parkinson Disease; Prodrugs; Rats | 2014 |
Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study.
Topics: Aged; Antiparkinson Agents; Brachial Artery; Catechols; Dilatation; Endothelium; Female; Homocysteine; Humans; Hyperhomocysteinemia; Levodopa; Logistic Models; Male; Middle Aged; Nitriles; Parkinson Disease; Statistics, Nonparametric | 2014 |
Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
Topics: Adenosine Triphosphate; Animals; Antiparkinson Agents; Benzophenones; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cell Survival; Cells, Cultured; Hepatocytes; Humans; Levodopa; Male; Membrane Potential, Mitochondrial; Models, Biological; Nitriles; Nitrophenols; Oxadiazoles; Rats, Wistar; Tolcapone | 2015 |
Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.
Topics: Benzophenones; Blood Chemical Analysis; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Nitriles; Nitrophenols; Quality Control; Reproducibility of Results; Tandem Mass Spectrometry; Tolcapone; Tyrosine | 2015 |
Entacapone and prostate cancer risk in patients with Parkinson's disease.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Cohort Studies; Drug Therapy, Combination; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Prostatic Neoplasms; Registries; Risk; Time Factors | 2015 |
Yokukansan, a Traditional Japanese Medicine, Enhances the L-DOPA-Induced Rotational Response in 6-Hydroxydopamine-Lesioned Rats: Possible Inhibition of COMT.
Topics: Animals; Benserazide; Catechols; Cell Line; Corpus Striatum; Dopamine; Drugs, Chinese Herbal; Hydrazines; Levodopa; Male; Medicine, East Asian Traditional; Nitriles; Oxidopamine; Pargyline; Rats; Rats, Wistar | 2016 |
Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers.
Topics: Adult; Carbidopa; Catechols; Cocaine; Cocaine-Related Disorders; Drug Interactions; Face; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Smoke; Young Adult | 2016 |
Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.
Topics: Animals; Caproates; Capsules; Carbidopa; Catechols; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Humans; Hydrophobic and Hydrophilic Interactions; Lactones; Levodopa; Microscopy, Confocal; Nitriles; Parkinson Disease; Polyesters | 2016 |
3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA.
Topics: Animals; Astrocytes; Catechol O-Methyltransferase Inhibitors; Catechols; Cells, Cultured; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relationship, Drug; Glutathione; Levodopa; Mesencephalon; Neuroprotection; Neuroprotective Agents; Nitriles; Rats, Sprague-Dawley; Tyrosine | 2016 |
Investigation of different spectrophotometric and chemometric methods for determination of entacapone, levodopa and carbidopa in ternary mixture.
Topics: Calibration; Carbidopa; Catechols; Least-Squares Analysis; Levodopa; Limit of Detection; Nitriles; Principal Component Analysis; Reproducibility of Results; Spectrophotometry | 2017 |
Cathecol-O-methyltransferase inhibitors: another possibly useful pharmacological tool for treating Parkinson's disease in pregnancy?
Topics: Adult; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cesarean Section; Female; Gestational Age; Humans; Infant, Newborn; Levodopa; Nitriles; Parkinson Disease; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2017 |
Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices.
Topics: Antiparkinson Agents; Benserazide; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Levodopa; Molecular Structure; Nitriles | 2017 |
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.
Topics: Aged; Antiparkinson Agents; Catechols; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Oxadiazoles; Parkinson Disease; Treatment Outcome | 2018 |
Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Biological Availability; Brain Chemistry; Capsules; Carbidopa; Catechols; Dopamine; Drug Compounding; Female; Hydrophobic and Hydrophilic Interactions; Levodopa; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Nitriles; Parkinson Disease | 2018 |
Micellar HPLC-UV method for the simultaneous determination of levodopa, carbidopa and entacapone in pharmaceuticals and human plasma.
Topics: Adult; Carbidopa; Catechols; Chromatography, High Pressure Liquid; Humans; Levodopa; Limit of Detection; Linear Models; Male; Nitriles; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tablets | 2018 |
The influence of levodopa, entacapone and homocysteine on prevalence of polyneuropathy in patients with Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Catechols; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Polyneuropathies; Statistics, Nonparametric | 2018 |
Managing treatment fluctuations in Parkinson disease: "On" again-, "off" again.
Topics: Carbidopa; Catechols; Humans; Levodopa; Nitriles; Parkinson Disease | 2019 |
Dyskinesia-Hyperpyrexia Syndrome in Parkinson's disease with Deep Brain Stimulation and high-dose levodopa/carbidopa and entacapone.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Combined Modality Therapy; Deep Brain Stimulation; Drug Combinations; Drug Therapy, Combination; Fever; Humans; Hyperkinesis; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease | 2019 |
Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.
Topics: Antiparkinson Agents; Catechols; Cross-Sectional Studies; Dopamine; Dopamine Agonists; Genotype; Humans; Indans; Levodopa; Motor Activity; Nitriles; Parkinson Disease; Polymorphism, Single Nucleotide; Receptors, Dopamine D1; Receptors, Dopamine D3; Selegiline | 2019 |
A Real-Life Search for the Optimal Set of Conversion Factors to Levodopa-Equivalent-Dose in Parkinson's Disease Patients on Polytherapy.
Topics: Aged; Amantadine; Antiparkinson Agents; Catechols; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Nitriles; Outcome Assessment, Health Care; Parkinson Disease; Retrospective Studies | 2020 |
A rapid liquid chromatography/tandem mass spectrometry method for simultaneous determination of levodopa, carbidopa, entacapone and their six related compounds in film-coated tablets.
Topics: Carbidopa; Catechols; Chromatography, High Pressure Liquid; Levodopa; Limit of Detection; Linear Models; Nitriles; Reproducibility of Results; Tablets; Tandem Mass Spectrometry | 2020 |
Remarkable clinical responses of non-fluctuating Parkinson's disease (PD) after alternating catechol O-methyltransferase inhibitors: case series switching from entacapone 200 ~ 300 mg/day to opicapone 25 mg/day.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease | 2021 |
Entacapone - Another Parkinson's medication associated with lymphocytic colitis.
Topics: Antiparkinson Agents; Catechols; Colitis, Lymphocytic; Enzyme Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease | 2021 |
Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer.
Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase; Catechols; Drug Therapy, Combination; Humans; Levodopa; Nitriles; Parkinson Disease; United States; United States Food and Drug Administration | 2022 |
A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease.
Topics: Adenosine Deaminase; Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Gastrointestinal Microbiome; Humans; Intercellular Signaling Peptides and Proteins; Levodopa; Nitriles; Parkinson Disease; Pilot Projects; RNA, Ribosomal, 16S | 2022 |
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Homocysteine; Humans; Levodopa; Nitriles; Oxadiazoles; Parkinson Disease | 2022 |
Lymphocytic colitis associated with entacapone.
Topics: Antiparkinson Agents; Catechols; Colitis, Lymphocytic; Humans; Levodopa; Nitriles | 2022 |
Different dissolution conditions affect stability and dissolution profiles of bioequivalent levodopa-containing oral dosage forms.
Topics: Carbidopa; Drugs, Generic; Humans; Levodopa; Solubility; Therapeutic Equivalency | 2022 |
A novel treatment option for intrajejunal levodopa administration.
Topics: Antiparkinson Agents; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease | 2023 |
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Nitriles; Parkinson Disease; Retrospective Studies | 2023 |
Apprends-moi l'art des petits pas: Levodopa, Carbidopa Intestinal Gel plus Entacapone.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Prospective Studies | 2023 |
Opicapone versus entacapone: Head-to-head retrospective data-based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol-O-methyltransferase (COMT) inhibitor treatment.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Oxadiazoles; Parkinson Disease; Patient Acceptance of Health Care; Retrospective Studies | 2023 |